menu
    • menu
    [{"orgOrder":0,"company":"Follicum AB","sponsor":"proDERM GmbH | Hair and Skin Institute, Charit\u00e9, Berlin, Germany | CentroDerm","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"FOL- 005","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Follicum AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Follicum AB \/ proDERM GmbH | Hair and Skin Institute, Charit\u00e9, Berlin, Germany | CentroDerm","highestDevelopmentStatusID":"8","companyTruncated":"Follicum AB \/ proDERM GmbH | Hair and Skin Institute, Charit\u00e9, Berlin, Germany | CentroDerm"},{"orgOrder":0,"company":"Follicum AB","sponsor":"Bioskin GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"FOL-005","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Follicum AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Follicum AB \/ Bioskin GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Follicum AB \/ Bioskin GmbH"},{"orgOrder":0,"company":"Follicum AB","sponsor":"Bioskin GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"FOL-005","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Follicum AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Follicum AB \/ Bioskin GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Follicum AB \/ Bioskin GmbH"},{"orgOrder":0,"company":"Follicum AB","sponsor":"Bioskin GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"FOL-005","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Follicum AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Follicum AB \/ Bioskin GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Follicum AB \/ Bioskin GmbH"},{"orgOrder":0,"company":"Follicum AB","sponsor":"Bioskin","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Peptide, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"FOL-005","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Follicum AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Follicum AB \/ Bioskin","highestDevelopmentStatusID":"8","companyTruncated":"Follicum AB \/ Bioskin"},{"orgOrder":0,"company":"Follicum AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Peptide, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"FOL-005","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Follicum AB","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Follicum AB \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Follicum AB \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Follicum AB

    Menu

    Follicum AB

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Follicum AB

                            Sweden arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Follicum AB

                            Sweden arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : FOL- 005

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : proDERM GmbH | Hair and Skin Institute, Charité, Berlin, Germany | CentroDerm

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase 2a Trial of FOL-005 Topical Formulations to Investigate Hair Growth Potential and Safety in Healthy Ma...

                            Details : FOL- 005 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Alopecia.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            March 01, 2021

                            Lead Product(s) : FOL- 005

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : proDERM GmbH | Hair and Skin Institute, Charité, Berlin, Germany | CentroDerm

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Follicum AB

                            Sweden arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Follicum AB

                            Sweden arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : FOL-005

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Bioskin GmbH

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Follicum AB Reports that All Patients Have Completed Treatment With FOL-005 in the Phase II Study Against Hair...

                            Details : FOL-005 is a modified, short version of the endogenous protein, osteopontin. The ongoing double-blind and placebo-controlled Phase IIa study examines the safety and efficacy of FOL-005 in a new, cream-like formulation.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            January 28, 2021

                            Lead Product(s) : FOL-005

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Bioskin GmbH

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Follicum AB

                            Sweden arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Follicum AB

                            Sweden arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : FOL-005

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Bioskin GmbH

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            All patients included in Follicum’s Phase II Study with FOL-005 for Stimulation of Hair Growth

                            Details : The ongoing double-blind and placebo-controlled Phase II study examines the safety and efficacy of FOL-005 in a new, cream-like formulation. Patients themselves apply one of three different strengths of FOL-005 or placebo to the scalp once a day.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            October 08, 2020

                            Lead Product(s) : FOL-005

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Bioskin GmbH

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Follicum AB

                            Sweden arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Follicum AB

                            Sweden arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : FOL-005

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Bioskin GmbH

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Follicum Re-Starts phase II Study With FOL-005 for Stimulation of Hair Growth and Expands the Number of Study ...

                            Details : In two previous clinical studies, FOL-005 administered as an intradermal injection has been shown to be an effective and safe treatment for stimulation of hair growth.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            June 03, 2020

                            Lead Product(s) : FOL-005

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Bioskin GmbH

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Follicum AB

                            Sweden arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Follicum AB

                            Sweden arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : FOL-005

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Bioskin

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            To Investigate Efficacy of FOL-005 on Hair Growth on Scalp Skin

                            Details : FOL-005 is a Peptide drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Alopecia.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            March 16, 2018

                            Lead Product(s) : FOL-005

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Bioskin

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Follicum AB

                            Sweden arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Follicum AB

                            Sweden arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : FOL-005

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Investigation of FOL-005 on Clinical Safety and Effect on Hair Growth

                            Details : FOL-005 is a Peptide drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Hypertrichosis.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            June 08, 2016

                            Lead Product(s) : FOL-005

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth